BridgeBio Pharma BBIO EPS (Basic)
EPS (Basic) at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareBasic.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's eps (basic).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's EPS (basic)?
- BridgeBio Pharma (BBIO) reported EPS (basic) of -$0.84 in Q1 2026.
- How has BridgeBio Pharma's EPS (basic) changed year-over-year?
- BridgeBio Pharma's EPS (basic) increased by 4.5% year-over-year, from -$0.88 to -$0.84.
- What is the long-term trend for BridgeBio Pharma's EPS (basic)?
- Over 4 years (2021 to 2025), BridgeBio Pharma's EPS (basic) has grown at a -0.8% compound annual growth rate (CAGR), from -$3.90 to -$3.77.
- What does EPS (basic) mean?
- The portion of a company's profit allocated to each share of common stock, excluding potential dilution.
- How do you interpret EPS (basic)?
- Higher EPS indicates greater profitability per share, which is generally positive for stock valuation.
- How does EPS (basic) compare across companies?
- Standard metric used by investors to compare profitability across companies of different sizes.